Ectica Technologies

Executive Summary

Ectica Technologies is a Swiss life science company pioneering advanced synthetic hydrogel-based in vitro and ex vivo models for cancer and fibrosis research. Its core platform, 3DProSeed®, automates the creation of animal-free tumor stromal models that closely replicate the tumor microenvironment, enabling more accurate drug screening. Serving contract research organizations (CROs), biopharma companies, and CDMOs, Ectica offers both standardized products and custom development services. Founded in 2017 and currently in the pre-clinical stage, the company is positioned to address the growing demand for animal-free, high-throughput screening tools. With its innovative hydrogel technology, Ectica aims to reduce reliance on animal models and improve predictivity in drug development, potentially accelerating timelines for oncology and fibrosis therapeutics.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Round70% success
• Q4 2026Strategic Partnership with a Top CRO60% success
• TBDLaunch of 3DProSeed® for Fibrosis Models80% success